Figure 1.
A hypothetical cohort of 1000 children with SCA and strokes followed for 5 years who either received no therapy, hydroxyurea therapy, or regular blood transfusion therapy. The figure depicts the number of children in the cohort with stroke recurrence in the no treatment group, hydroxyurea therapy group, and regular blood transfusion therapy group with expected incidence rates of 29.1 (95% CI, 19.2-38.9), 3.8 (95% CI, 1.9-5.7), and 1.9 (95 CI, 1.0-2.9) events per 100 patient-years, respectively.12 Figure reproduced from DeBaun and Kirkham.13
